Page 290 - Vitamin D and Cancer

11 Vitamin D and Hematologic Malignancies 277

137. Binderup L, Bramm E (Mar 1, 1988) Effects of a novel vitamin D analogue MC903 on cell
proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem
Pharmacol 37(5):889–95
138. Müller K, Svenson M, Bendtzen K (Apr, 1988) 1 alpha,25-Dihydroxyvitamin D3 and a novel
vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. Immunol
Lett 17(4):361–5
139. Müller K, Heilmann C, Poulsen LK, Barington T, Bendtzen K (Mar-Apr, 1991) The role of
monocytes and T cells in 1,25-dihydroxyvitamin D3 mediated inhibition of B cell function
in vitro. Immunopharmacology 21(2):121–8
140. Rebel VI, Ossenkoppele GJ, van de Loosdrecht AA, Wijermans PW, Beelen RH,
Langenhuijsen MM (1992) Monocytic differentiation induction of HL-60 cells by MC 903,
a novel vitamin D analogue. Leuk Res 16(5):443–51
141. Jung SJ, Lee YY, Pakkala S, de Vos S, Elstner E, Norman AW, Green J, Uskokovic M,
Koeffler HP (June 1994) 1,25(OH)2–16ene-vitamin D3 is a potent antileukemic agent with
low potential to cause hypercalcemia. Leuk Res 18(6):453–63
142. Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP (Aug 15, 1999)
5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate,
breast, and myeloid leukemic cells. Cancer Res 59(16):4023–9
143. Pakkala S, de Vos S, Elstner E, Rude RK, Uskokovic M, Binderup L, Koeffler HP (Jan,
1995) Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on
serum calcium levels. Leuk Res 19(1):65–72
144. Brown AJ, Dusso A, Slatopolsky E (Mar, 1994) Selective vitamin D analogs and their thera-
peutic applications. Semin Nephrol 14(2):156–74
145. Zhou JY, Norman AW, Chen DL, Sun GW, Uskokovic M, Koeffler HP (May, 1990)
1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc
Natl Acad Sci USA 87(l0):3929–32
146. Campbell MJ, Reddy GS, Koeffler HP (Sep 1, 1997) Vitamin D3 analogs and their 24-oxo
metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing
molecular effects. J Cell Biochem 66(3):413–25
147. Shiohara M, Uskokovic M, Hisatake J, Hisatake Y, Koike K, Komiyama A, Koeffler HP
(Apr 15, 2001) 24-Oxo metabolites of vitamin D3 analogues: disassociation of their
prominent antileukemic effects from their lack of calcium modulation. Cancer Res
61(8):3361–8
148. Binderup L, Latini S, Binderup E, Bretting C, Calverley M, Hansen K (Sep 27, 1991) 20-epi-
vitamin D3 analogues: a novel class of potent regulators of cell growth and immune
responses. Biochem Pharmacol 42(8):1569–75
149. Elstner E, Lee YY, Hashiya M, Pakkala S, Binderup L, Norman AW, Okamura WH, Koeffler
HP (Sep 15, 1994) 1 alpha,25-Dihydroxy-20-epi-vitamin D3: an extraordinarily potent
inhibitor of leukemic cell growth in vitro. Blood 84(6):1960–7
150. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A,
Slatopolsky E (Oct, 1998) Suppression of parathyroid hormone secretion in hemodialysis
patients by a novel vitamin D analogue: 19-nor- l,25-dihydroxyvitamin D2. Am J Kidney Dis
32(2 Suppl 2):S48–54
151. Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J (Aug, 1998)
19-Nor-l-alpha-25 dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the
levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol
9(8):1427–32
152. Molnár I, Kute T, Willingham MC, Powell BL, Dodge WH, Schwartz GG (Jan, 2003)
19-nor-lalpha,25 dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation,
differentiation, and apoptosis in human leukemic cell lines. J Cancer Res Clin Oncol
129(1):35–42
153. Molnár I, Kute T, Willingham MC, Schwartz GG (May, 2004) 19-Nor-lalpha,25-
dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at
clinically achievable concentrations. J Steroid Biochem Mol Biol 89–90(1–5):539–43